Investigational drug · Phase 2
PIPE-791
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "PIPE-791"
First trial start
2026
Jan 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PIPE-791", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "PIPE-791" as an intervention, largest first.
- Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Contineum TherapeuticsIndustry
NCT07284459 · 324 participants (planned) · Start Jan 8, 2026 · Primary completion May 2028
Drug: PIPE-791 Dose A; PIPE-791 Dose B and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Mar del Plata, Argentina; Quilmes, Argentina; Buenos Aires, Argentina · 113 sites in all
Contineum TherapeuticsIndustry
NCT05983939 · 56 participants · Start Jun 26, 2023 · Primary completion Feb 1, 2024
Drug: PIPE-791; Placebo · For: Multiple Sclerosis
Sites: San Antonio, Texas
Contineum TherapeuticsIndustry
NCT06810245 · 43 participants · Start Feb 4, 2025 · Primary completion Jan 20, 2026
Drug: PIPE-791; Placebo · For: Chronic Osteoarthritis Pain; Chronic Low Back Pain
Sites: Phoenix, Arizona; Marietta, Georgia; Hartsdale, New York · 5 sites in all
Contineum TherapeuticsIndustry
NCT06683612 · 16 participants · Start Dec 9, 2024 · Primary completion Jun 4, 2025
Drug: PIPE-791 · For: Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary Fibrosis; Multiple Sclerosis and 6 more
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.
Chen A, Baccei C, Baccei J, et al. · J Med Chem 2026
- Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma.
Kocherlakota S, Nicol A, Locri F, et al. · Transl Vis Sci Technol 2026
- Reduced activation of pain-related brain regions with lysophosphatidic acid receptor subtype-1 antagonist PIPE-791 in a nonhuman primate model of chronic peripheral neuropathy.
Hama A, Baccei C, Chen A, et al. · Neuropharmacology 2025
- The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis.
Poon M, Lorrain K, Broadhead A, et al. · Respir Res 2025
- Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis.
Poon MM, Lorrain KI, Stebbins KJ, et al. · Sci Rep 2024
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.